Fulgent Genetics Stock Price, Forecast & Analysis (NASDAQ:FLGT)

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Fulgent Genetics Inc (NASDAQ:FLGT) released its earnings results on Monday, November, 4th. The company reported $0.09 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.01 by $0.08. The company earned $10.35 million during the quarter, compared to the consensus estimate of $8.48 million. Fulgent Genetics had a negative net margin of 3.52% and a negative return on equity of 0.16%. View Fulgent Genetics' Earnings History.

Fulgent Genetics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Fulgent Genetics.

2 brokers have issued twelve-month price targets for Fulgent Genetics' shares. Their forecasts range from $12.30 to $12.30. On average, they expect Fulgent Genetics' stock price to reach $12.30 in the next year. This suggests a possible upside of 15.2% from the stock's current price. View Analyst Price Targets for Fulgent Genetics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fulgent Genetics.

Media coverage about FLGT stock has been trending somewhat negative recently, InfoTrie reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Fulgent Genetics earned a media sentiment score of -1.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Fulgent Genetics.

Fulgent Genetics saw a decrease in short interest in October. As of October 31st, there was short interest totalling 96,200 shares, a decrease of 29.1% from the September 30th total of 135,700 shares. Based on an average trading volume of 137,100 shares, the days-to-cover ratio is presently 0.7 days. Approximately 1.5% of the company's shares are sold short. View Fulgent Genetics' Current Options Chain.

Some companies that are related to Fulgent Genetics include CareDx (CDNA), RadNet (RDNT), Castle Biosciences (CSTL), Personalis (PSNL), Celcuity (CELC), Enzo Biochem (ENZ), Psychemedics (PMD), PotNetwork (POTN), Miragen Therapeutics (MGEN), Biocept (BIOC), Avant Diagnostics (AVDX), CBA Florida (CBAI), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX) and OpGen (OPGN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include Crispr Therapeutics (CRSP), Zynerba Pharmaceuticals (ZYNE), Baidu (BIDU), Baozun (BZUN), Catalyst Pharmaceuticals (CPRX), Canopy Growth (CGC), Corbus Pharmaceuticals (CRBP), Intellia Therapeutics (NTLA), Alibaba Group (BABA) and InVitae (NVTA).

(FLGT) raised $60 million in an initial public offering on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Fulgent Genetics' stock is owned by many different of retail and institutional investors. Top institutional investors include Raymond James Trust N.A. (2.70%), Essex Investment Management Co. LLC (0.66%), Mutual Advisors LLC (0.57%) and Russell Investments Group Ltd. (0.01%). Company insiders that own Fulgent Genetics stock include Ming Hsieh and Paul Kim. View Institutional Ownership Trends for Fulgent Genetics.

FLGT stock was sold by a variety of institutional investors in the last quarter, including Mutual Advisors LLC and Essex Investment Management Co. LLC. View Insider Buying and Selling for Fulgent Genetics.

FLGT stock was bought by a variety of institutional investors in the last quarter, including Raymond James Trust N.A. and Russell Investments Group Ltd.. View Insider Buying and Selling for Fulgent Genetics.

Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FLGT stock can currently be purchased for approximately $10.68.

Fulgent Genetics has a market capitalization of $199.82 million and generates $21.36 million in revenue each year. The company earns $-5,610,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Fulgent Genetics employs 123 workers across the globe.View Additional Information About Fulgent Genetics.

The official website for Fulgent Genetics is http://www.fulgentgenetics.com/.

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE SUITE 205, TEMPLE CITY CA, 91780. The company can be reached via phone at 626-350-0537 or via email at [email protected]